抗原
溶瘤病毒
癌症疫苗
癌症免疫疗法
免疫疗法
医学
疫苗疗法
癌症
癌症研究
接种疫苗
免疫学
免疫系统
内科学
作者
Karita Peltonen,Sara Feola,Husen M. Umer,Jacopo Chiaro,Georgios Mermelekas,Erkko Ylösmäki,Saila K. Pesonen,Rui M. Branca,Janne Lehtiö,Vincenzo Cerullo
出处
期刊:Cancers
[MDPI AG]
日期:2021-07-07
卷期号:13 (14): 3408-3408
被引量:17
标识
DOI:10.3390/cancers13143408
摘要
Knowledge of clinically targetable tumor antigens is becoming vital for broader design and utility of therapeutic cancer vaccines. This information is obtained reliably by directly interrogating the MHC-I presented peptide ligands, the immunopeptidome, with state-of-the-art mass spectrometry. Our manuscript describes direct identification of novel tumor antigens for an aggressive triple-negative breast cancer model. Immunopeptidome profiling revealed 2481 unique antigens, among them a novel ERV antigen originating from an endogenous retrovirus element. The clinical benefit and tumor control potential of the identified tumor antigens and ERV antigen were studied in a preclinical model using two vaccine platforms and therapeutic settings. Prominent control of established tumors was achieved using an oncolytic adenovirus platform designed for flexible and specific tumor targeting, namely PeptiCRAd. Our study presents a pipeline integrating immunopeptidome analysis-driven antigen discovery with a therapeutic cancer vaccine platform for improved personalized oncolytic immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI